Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments

被引：71

作者：

Mcintosh, Stuart A. ^{[1
]}

Alam, Fareeha ^{[2
]}

Adams, Laura ^{[3
]}

Boon, Ian S. ^{[4
]}

Callaghan, Jonathan ^{[1
]}

Conti, Isabella ^{[1
]}

Copson, Ellen ^{[4
,5
]}

Carson, Victoria ^{[1
]}

Davidson, Mitchell ^{[1
]}

Fitzgerald, Helen ^{[7
]}

Gautam, Ashram ^{[8
]}

Jones, Christopher M. ^{[9
]}

Kargbo, Saffron ^{[1
]}

Lakshmipathy, Gokul ^{[1
]}

Maguire, Hannah ^{[1
]}

Mcferran, Kathryn ^{[1
]}

Mirandari, Amatta ^{[5
]}

Moore, Natasha ^{[1
]}

Moore, Ross ^{[1
]}

Murray, Aidan ^{[1
]}

Newman, Lydia ^{[4
]}

Robinson, Stephen D. ^{[10
]}

Segaran, Ashvina ^{[11
]}

Soong, Chin Nam ^{[1
]}

Walker, Andrew ^{[1
]}

Wijayaweera, Kusal ^{[6
]}

Atun, Rifat ^{[12
,13
]}

Cutress, Ramsey, I ^{[4
,5
]}

Head, Michael G. ^{[6
]}

机构：

[1] Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Sch Med Dent & Biomed Sci, Belfast BT9 7AE, North Ireland

[2] UCL, London, England

[3] St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Dept Oncol, Leeds, England

[4] Univ Hosp Southampton NHS Fdn Trust, Southampton, England

[5] Univ Southampton, Fac Med, Canc Sci Acad Unit, Southampton, England

[6] Univ Southampton, Fac Med, Clin Informat Res Unit, Southampton, England

[7] Velindre Canc Ctr, Cardiff, Wales

[8] Newcastle Upon Tyne Hosp NHS Fdn Trust, Northern Ctr Canc Care, Newcastle Upon Tyne, England

[9] Univ Cambridge, Dept Oncol, Cambridge, England

[10] Univ Hosp Sussex NHS Fdn Trust, Sussex Canc Ctr, Brighton, England

[11] Univ Oxford, Ludwig Inst Canc Res, Nuffield Dept Med, Oxford, England

[12] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Dept Hlth Policy & Management, Boston, MA USA

[13] Harvard Univ, Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA USA

来源：

LANCET ONCOLOGY | 2023年 / 24卷 / 06期

关键词：

COUNTRIES;

D O I：

10.1016/S1470-2045(23)00182-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Cancer is a leading cause of disease burden globally, with more than 19 & BULL;3 million cases and 10 million deaths recorded in 2020. Research is crucial to understanding the determinants of cancer and the effects of interventions, and to improving outcomes. We aimed to analyse global patterns of public and philanthropic investment in cancer research.Methods In this content analysis, we searched the UberResearch Dimensions database and Cancer Research UK data for human cancer research funding awards from public and philanthropic funders between Jan 1, 2016, and Dec 31, 2020. Included award types were project and programme grants, fellowships, pump priming, and pilot projects. Awards focused on operational delivery of cancer care were excluded. Awards were categorised by cancer type, cross-cutting research theme, and research phase. Funding amount was compared with global burden of specific cancers, measured by disability-adjusted life-years, years lived with disability, and mortality using data from the Global Burden of Disease study. Findings We identified 66 388 awards with total investment of about US$24 & BULL;5 billion in 2016-20. Investment decreased year-on-year, with the largest drop observed between 2019 and 2020. Pre-clinical research received 73 & BULL;5% of the funding across the 5 years ($18 billion), phase 1-4 clinical trials received 7 & BULL;4% ($1 & BULL;8 billion), public health research received 9 & BULL;4% ($2 & BULL;3 billion), and cross-disciplinary research received 5 & BULL;0% ($1 & BULL;2 billion). General cancer research received the largest investment ($7 & BULL;1 billion, 29 & BULL;2% of the total funding). The most highly funded cancer types were breast cancer ($2 & BULL;7 billion [11 & BULL;2%]), haematological cancer ($2 & BULL;3 billion [9 & BULL;4%]), and brain cancer ($1 & BULL;3 billion [5 & BULL;5%]). Analysis by cross-cutting theme revealed that 41 & BULL;2% of investment ($9 & BULL;6 billion) went to cancer biology research, 19 & BULL;6% ($4 & BULL;6 billion) to drug treatment research, and 12 & BULL;1% ($2 & BULL;8 billion) to immuno-oncology. 1 & BULL;4% of the total funding ($0 & BULL;3 billion) was spent on surgery research, 2 & BULL;8% ($0 & BULL;7 billion) was spent on radiotherapy research, and 0 & BULL;5% ($0 & BULL;1 billion) was spent on global health studies.Interpretation Cancer research funding must be aligned with the global burden of cancer with more equitable funding for cancer research in low-income and middle-income countries (which account for 80% of cancer burden), both to support research relevant to these settings, and build research capacity within these countries. There is an urgent need to prioritise investment in surgery and radiotherapy research given their primacy in the treatment of many solid tumours.

引用

页码：636 / 645

页数：10

共 23 条

[1] Trends in International Cancer Research Investment 2006-2018 [J].

Abudu, Rachel ;

Bouche, Gauthier ;

Bourougaa, Karima ;

Davies, Lynne ;

Duncan, Kalina ;

Estaquio, Carla ;

Font, Anna Diaz ;

Hurlbert, Marc S. ;

Jackson, Paul ;

Kroeskop-Bossenbroek, Linda ;

Lewis, Ian ;

Mitrou, Giota ;

Mutabbir, Abdul ;

Pettigrew, Christopher A. ;

Turner, Lynn ;

Weerman, Annemarie ;

Wojtanik, Kari .

JCO GLOBAL ONCOLOGY, 2021, 7 :602-610

[2] The evolution of the disability-adjusted life year (DALY) [J].

Chen, Ariel ;

Jacobsen, Kathryn H. ;

Deshmukh, Ashish A. ;

Cantor, Scott B. .

SOCIO-ECONOMIC PLANNING SCIENCES, 2015, 49 :10-15

[3] Is Clinical Research Serving the Needs of the Global Cancer Burden? An Analysis of Contemporary Global Radiation Therapy Randomized Controlled Trials [J].

Dodkins, Joanna ;

Hopman, Wilma M. ;

Wells, John Connor ;

Lievens, Yolande ;

Malik, R. A. ;

Pramesh, C. S. ;

Gyawali, Bishal ;

Hammad, Nazik ;

Mukherji, Deborah ;

Sullivan, Richard ;

Parkes, Jeannette ;

Booth, Christopher M. ;

Aggarwal, Ajay .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 113 (03) :500-508

[4] Global Inequities in Precision Medicine and Molecular Cancer Research [J].

Drake, Thomas M. ;

Knight, Stephen R. ;

Harrison, Ewen M. ;

Soreide, Kjetil .

FRONTIERS IN ONCOLOGY, 2018, 8

[5] Ebola research funding: a systematic analysis, 1997-2015 [J].

Fitchett, Joseph R. A. ;

Lichtman, Amos ;

Soyode, Damilola T. ;

Low, Ariel ;

de Onis, Jimena Villar ;

Head, Michael G. ;

Atun, Rifat .

JOURNAL OF GLOBAL HEALTH, 2016, 6 (02)

[6] Transparency and availability of data for cancer research [J].

Fitchett, Joseph R. A. ;

Sharara, Nour ;

Head, Michael G. ;

Huang, Franklin ;

Atun, Rifat .

LANCET, 2016, 388 (10047) :866-867

[7]

Head MG, 2020, LANCET GLOB HEALTH, V8, pE1295, DOI 10.1016/S2214-109X(20)30357-0

[8]

IHME and GHDx, GLOBAL BURDEN DIS 20

[9]

Lawler M, 2023, LANCET ONCOL, V24, pE11, DOI 10.1016/S1470-2045(22)00540-X

[10] Provision and use of radiotherapy in Europe [J].

Lievens, Yolande ;

Borras, Josep M. ;

Grau, Cai .

MOLECULAR ONCOLOGY, 2020, 14 (07) :1461-1469

← 1 2 3 →